top of page
  • Writer's picturegpacunitedterridiaz

GPAC's Official Statement

Updated: Jun 13

On June 12, 2024 the American Society of Plastic Surgeons and

the Aesthetic Society released a joint statement about breast

implant removal terminology, a statement that is based on very

limited data and research about proper removal techniques for

breast implant removal.

The Global Patient Advocacy Coalition does not support this

statement due to the current lack of scientific evidence. In short

“we don’t know what we don’t know”. GPAC will continue to

monitor ongoing research that is being conducted in an effort to

learn more about the health impacts of different methods of

breast implant removal.

This press release contradicts the expert opinions of many plastic

surgeons who treat breast implant illness patients and patients

who have developed cancer from breast implants. Recently, in

April 2024, the 5th World Consensus Conference on BIA-ALCL was

held in Rome, Italy. Many surgeons at the conference expressed

concerns about breast implant-related cancers and made

statements in their presentations about the importance of proper

complete removal of breast implant capsules.

Additionally, the American Association of Plastic Surgeons

recently issued a statement in March 2024 which concluded it is

considered reasonable to prophylactically remove textured breast

implants to reduce the risk of cancer. This statement was

supported by numerous global experts in the plastic surgery

community, as well as all of the explant surgeons that our GPAC

team collaborates with.

It is important to note the history of deception by the plastic

surgeon societies that are represented in this statement. In 2011,

after the FDA announced BIA-ALCL, an emerging breast implant

related cancer, the societies launched a joint educational

campaign to dismiss and downplay the cancer that is caused by

breast implants. Public Citizen reported that the societies

“urged members to inaccurately downplay the significance of recent

evidence about the risks of breast implant-related cancer when

speaking to female patients during a recent members-only webinar

posted on the ASPS and ASAPS websites. Such communications

represented a deplorable attempt to trivialize the significance of the

findings of increased numbers of cases of a rare form of cancer, called

anaplastic large cell lymphoma (ALCL), in women with breast implants.

Public Citizen called on the FDA to stop this deliberately misleading

messaging campaign, the goal of which apparently was to keep

women in the dark about the dangers of breast implants so they will

continue to ask for them.” (read full article here)

GPAC was initially invited to participate in the Breast Surgery

Collaborative Community (BSCC), but the experience has resulted

in both GPAC members (Robyn Towt and Terri Diaz) resigning

from the committee, as it did not align with our views on patient

safety and improving standard of care for all patients.

It is our hope that the Breast Implant Illness community and

explant surgeons understand that this statement does not reflect

the views of all plastic surgeons, and directly contradicts opinions

of surgeons, oncologists, radiologists, immunologists, and

pathologists who work extensively with explant patients and

patients who have developed breast implant-related cancers.

GPAC continues to proudly participate in projects that only serve

the best interests of patients and we are committed to continuing

to serve the patient community in an honorable manner. We look

forward to providing our supporters with the latest information

regarding breast implants and medical device safety. Thank you

for your support!

125 views0 comments


bottom of page